Skip Navigation

Cardiovascular Research 2001 49(2):430-439; doi:10.1016/S0008-6363(00)00253-4
© 2001 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Brehm, B.R
Right arrow Articles by Schulze-Osthoff, K
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brehm, B.R
Right arrow Articles by Schulze-Osthoff, K
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2000, European Society of Cardiology

Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells

B.R Brehma,*, S.C Wolfa, D Bertscha, M Klaussnera, S Wesselborgb, S Schülerc and K Schulze-Osthoffd

aDepartment of Cardiology, University of Tübingen, Otfried-Müllerstrasse 10, 72076, Tübingen, Germany
bDepartment of Gastroenterology, University of Tübingen, Tübingen, Germany
cDepartment of Cardiosurgery, University of Dresden, Dresden, Germany
dDepartment of Immunology and Cell Biology, University of Münster, Münster, Germany

* Corresponding author. Tel.: +49-7071-298-2711; fax: +49-7071-360-245 bernard_brehm{at}compuserve.com

Objective: Secondary failure due to late restenosis continues to occur in 30–50% of individuals after PTCA. β-Blockers play an important role in the treatment of CAD. The aim of this study was to investigate the effects of the new β-blocker nebivolol on cell proliferation of human coronary smooth muscle cells (haCSMCs) and endothelial cells (haECs) in comparison to traditional β-blockers. Methods: The effect of nebivolol and other β-blockers on proliferation of HaECs and HaCSMCs was analyzed by bromodeoxyuridine incorporation. Apoptosis was measured by determination of hypodiploid DNA in both cell types. Additionally, in HaECs NO formation, endothelin-1 transcription and secretion were determined. Results: Incubation for 1, 2, 4, 7 or 14 days resulted in a concentration- and time-dependent reduction of proliferation up to 80% in HaECs and HaCSMCs. β-Blockers such as propranolol, metoprolol or bisoprolol did not exert this effect. Nebivolol inhibited accelerated haCSMC proliferation even in the presence of growth factors such as TGFβ1 and PDGF-BB. Nebivolol concentration-dependently induced a moderate apoptosis (10–5 mol/l: 23%) and a decrease of haCSMCs in the S-phase by 66%. HaECs showed comparable results. During nebivolol incubation NO formation of HaCEs increased, while endothelin-1 transcription and secretion were suppressed. Conclusion: Whereas classical β-blockers do not affect cell growth, only nebivolol inhibits haCSMC or haEC proliferation and induces a moderate rate of apoptosis. Furthermore, in HaCEs NO formation increases and endothelin-1 secretion decreases suggesting that nebivolol may represent a β-blocker with great promises in CAD therapy.

KEYWORDS Endothelial function; Endothelins; Restenosis; Smooth muscle


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Eur J Heart FailHome page
B. R. Brehm, S. C. Wolf, S. Gorner, N. Buck-Muller, and T. Risler
Effect of nebivolol on left ventricular function in patients with chronic heart failure: a pilot study
Eur J Heart Fail, December 1, 2002; 4(6): 757 - 763.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.